Q2 FY2026 · ended Jun 30, 2026 · Revenue $20.50M, -29.8% YoY · Filed Aug 13, 2026
OptimizeRx Corporation (OPRX) files with the SEC under industry code 7389, Services-Business Services, NEC. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $20.5 million and a net loss of $703,000. Free cash flow was $8.6 million. As of Jun 30, 2026 it held $24.1 million in cash and investments and $20.2 million in total debt.
Revenue
$20.50M
-29.8% vs year-ago quarter
Net income
$-703,000
-145.9% vs year-ago quarter
Operating cash flow
$8.61M
+88.8% vs year-ago quarter
Free cash flow
$8.58M
+88.4% vs year-ago quarter
EPS
$-0.04
-150.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
18.84M
+1.5% vs year-ago quarter
Net cash
$3.94M
Q2 FY2026
Operating margin
11.0%
TTM
Company profile
- Industry
- Services-Business Services, NEC (SIC 7389)
- Listed as
- OPRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1448431
Other Services-Business Services, NEC companies
- Visa Inc. V
- Mastercard Inc MA
- Alibaba Group Holding Ltd BABA
- Accenture plc ACN
- Uber Technologies, Inc UBER
- PDD Holdings Inc. PDD
- Mercadolibre Inc MELI
- DoorDash, Inc. DASH
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $20.5M | $19.8M | $32.2M | $26.1M | $29.2M |
| Operating income | -$88,000 | $396,000 | $8.6M | $2.0M | $3.2M |
| Net income | -$703,000 | -$495,000 | $5.0M | $779,000 | $1.5M |
| Diluted EPS | -$0.04 | -$0.03 | $0.27 | $0.04 | $0.08 |
| Operating cash flow | $8.6M | -$467,000 | $7.1M | $3.2M | $4.6M |
| Free cash flow | $8.6M | -$488,000 | $7.1M | $3.2M | $4.6M |
| Total assets | $164.3M | $167.3M | $176.9M | $170.3M | $169.3M |
| Total liabilities | $33.2M | $37.7M | $48.6M | $48.1M | $50.0M |
| Stockholders' equity | $131.1M | $129.6M | $128.3M | $122.3M | $119.3M |
| Cash and investments | $24.1M | $20.2M | $23.4M | $19.5M | $16.6M |
| Total debt | $20.2M | $24.0M | $26.7M | $29.3M | $29.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change, Regulation FD disclosure
|
Aug 12, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 12, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 5, 2026 | Jun 1, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, Results of operations, New debt
|
May 12, 2026 | May 12, 2026 |
All 1000 OptimizeRx Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.